Compounded Semaglutide in 2026: Is It Still Legal?
The FDA declared the semaglutide shortage resolved in 2025. Here's what that means for compounded GLP-1s and your treatment options.
If you've been getting affordable GLP-1 medications through a telehealth provider, you may have heard concerning news: the FDA officially declared the semaglutide shortage resolved in April 2025. But what does this actually mean for compounded medications, and are they still available?
Understanding the Shortage Status
Here's the timeline of events:
- 2022: FDA declares semaglutide (Ozempic, Wegovy) in shortage
- 2023-2024: Compounding pharmacies legally produce semaglutide
- April 2025: FDA removes semaglutide from shortage list
- 2025-2026: Legal gray area and transition period
What the Law Actually Says
Under the Federal Food, Drug, and Cosmetic Act, 503B compounding pharmacies can produce copies of FDA-approved drugs when those drugs are in shortage. Once a shortage is resolved, this legal protection technically ends.
However, the situation is more nuanced:
- Wind-down period: Pharmacies don't have to stop immediately
- Existing prescriptions: May be honored for continuity of care
- State laws vary: Some states have additional compounding protections
- Enforcement discretion: FDA hasn't aggressively targeted legitimate pharmacies
Current Availability (May 2026)
As of now, the landscape looks like this:
- Compounded semaglutide: Still available from some telehealth providers, but fewer options
- Compounded tirzepatide: More widely available (tirzepatide shortage not yet resolved)
- Prices: Have increased somewhat but still far below brand-name retail
- Provider policies: Varying approaches to continued compounding
What Are Your Options?
Option 1: Brand-Name with Insurance
If you have insurance that covers GLP-1s:
- Wegovy and Zepbound may be covered
- Copays vary widely ($25-500/month)
- Prior authorization usually required
- Most legitimate and sustainable long-term option
Option 2: Manufacturer Savings Programs
Both Novo Nordisk and Eli Lilly offer assistance programs:
- Wegovy savings card: Up to $500 off per month for eligible patients
- Zepbound savings card: Similar discounts available
- Income-based assistance programs for uninsured
Option 3: Compounded Tirzepatide
Since tirzepatide remains in shortage:
- Compounding is still clearly legal
- Many telehealth providers have shifted to tirzepatide
- Prices: $199-399/month typically
- May actually be more effective than semaglutide based on head-to-head trials
Option 4: Wait for Medicare Coverage
If you're on Medicare:
- Coverage begins mid-2026
- Copays as low as $50/month expected
- May be worth waiting if you can
Red Flags to Avoid
With the changing landscape, some bad actors have emerged. Avoid providers that:
- Claim to sell "generic Ozempic" or "generic Wegovy" (these don't exist)
- Ship from overseas pharmacies
- Don't require a prescription or medical consultation
- Have prices that seem too good to be true
- Can't provide information about their compounding pharmacy
The Bottom Line
The compounded GLP-1 landscape is shifting, but options still exist. If you're currently on compounded semaglutide, talk to your provider about transitioning to compounded tirzepatide, brand-name medications with insurance, or manufacturer assistance programs. The most important thing is to work with legitimate providers and avoid gray-market or overseas sources.
Affiliate Disclosure: We earn commissions from some provider links at no extra cost to you. This doesn't influence our rankings or reviews. Full disclosure
